Glycodiazine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317978

CAS#: 339-44-6

Description: Glycodiazine is a sulfapyrimidine derivative with antihyperglycemic activity. Like sulfonylureas, glymidine is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells and increasing the sensitivity of peripheral tissues to insulin. Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane.

Chemical Structure

img
Glycodiazine
CAS# 339-44-6
Instruction

Theoretical Analysis

MedKoo Cat#: 317978
Name: Glycodiazine
CAS#: 339-44-6
Chemical Formula: C13H15N3O4S
Exact Mass: 309.08
Molecular Weight: 309.340
Elemental Analysis: C, 50.47; H, 4.89; N, 13.58; O, 20.69; S, 10.37

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Glycodiazine; GLYMIDINE; Glycodiazine; Glidiazine; Glycodiazin; Glymidinum; Glycodiazin [German];

IUPAC/Chemical Name: N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide

InChi Key: QFWPJPIVLCBXFJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)

SMILES Code: COCCOC1=CN=C(N=C1)NS(=O)(=O)C2=CC=CC=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 309.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ullrich KJ, Rumrich G, Baumann K. Renal proximal tubular buffer-(glycodiazine)
transport. Inhomogeneity of local transport rate, dependence on sodium, effect of
inhibitors and chronic adaptation. Pflugers Arch. 1975 Jun 26;357(3-4):149-63.
PubMed PMID: 127986.


2: Ghanem MH, Guirgis FK. Effect of insulin and glycodiazine on the level of
plasma free fatty acids in bilharzial (schistosomal) hepatic fibrosis. J Trop Med
Hyg. 1972 Jun;75(6):115-8. PubMed PMID: 5044326.


3: Matsuno Z. [Histological studies on the pancreatic islets of Langerhans of
rabbits after long-term glycodiazine administration]. Nihon Naibunpi Gakkai
Zasshi. 1971 Jun 20;47(3):165-73. Japanese. PubMed PMID: 4934487.


4: Cheah JS, Tan BY. Evaluation of glycodiazine (Lycanol) in the treatment of
diabetes mellitus. Singapore Med J. 1970 Jun;11(2):91-5. PubMed PMID: 5505890.


5: Chugh RN, Bahl AL, Bhalla AS, Mathur KP. Trial of a new antidiabetic compound
(glycodiazine) in diabetes mellitus. J Indian Med Assoc. 1970 Jan 16;54(2):62-5.
PubMed PMID: 5418147.


6: Choi Y, Kreines K. Effect of glycodiazine on blood sugar in diabetes mellitus.
Diabetes. 1968 Aug;17(8):509-12. PubMed PMID: 4875654.


7: Chhetri MK, Pal K. Treatment of diabetes mellitus with glycodiazine. J Indian
Med Assoc. 1968 May 16;50(10):476-81. PubMed PMID: 5704866.


8: Camponovo LE, Maggi N. [On the pharmacology of the blood sugar decreasing
substance Glycodiazine]. Arzneimittelforschung. 1968 May;18(5):577-80. German.
PubMed PMID: 5755885.


9: [Current data on the action of glycodiazine]. Journ Annu Diabetol Hotel Dieu.
1968;9:433-7. French. PubMed PMID: 5748225.


10: Warembourg H, Jaillard J. [Experimentation with glycodiazine in the treatment
of diabetes. Apropos of 30 cases]. Lille Med. 1967 May;12(4):Suppl:516-9. French.
PubMed PMID: 5619705.


11: Janin J, Coing F, Cholat P, Bertrand JL, Potton F. [Oral therapy of diabetes
mellitus with glycodiazine. (Experimentation on 54 cases)]. Rev Lyon Med. 1967
Apr 30;16(8):333-40. French. PubMed PMID: 5607794.


12: Zavala A, Martí ML, Ruiz M, Busquet JC. [Clinical experience with
glycodiazine (Sh 717)]. Prensa Med Argent. 1967 Apr 14;54(7):313-5. Spanish.
PubMed PMID: 5614086.


13: Liberti R, Cicconetti C. [Oral therapy of diabetes mellitus with SH 717.
Glycodiazine or gondafon]. Minerva Med. 1967 Mar 21;58(23):978-87. Italian.
PubMed PMID: 6023633.


14: Thäle E. [Indication for the use of glycodiazine (Redul) as an oral
antidiabetic]. Med Welt. 1967 Feb 18;7:392-4. German. PubMed PMID: 6045243.


15: Scheiffarth F, Weist F, Warnatz H, Schnell K. [The presence of insulin
antibodies and the influence on insulin-protein binding of sulfonylurea and
glycodiazine]. Med Pharmacol Exp Int J Exp Med. 1967;17(1):17-24. German. PubMed
PMID: 6072678.


16: Eisenberg S, Cohen AM. Clinical trial of glycodiazine--a new oral
hypoglycemic drug. Isr J Med Sci. 1966 Nov-Dec;2(6):768-73. PubMed PMID: 5334155.


17: Camponovo LE, Maggi ND. [Pharmacologic study of a new hypoglycemic:
glycodiazine]. Prensa Med Argent. 1966 Aug 26;53(34):1857-62. Spanish. PubMed
PMID: 5998759.


18: Wasty SS, Hazell K. The value of glycodiazine ('Gondafon') for the elderly
diabetic. Br J Clin Pract. 1966 Aug;20(8):413-5. PubMed PMID: 5944031.


19: Moritz V, Häwert D. [Studies with glycodiazine on the islands of Langerhans
of inbred white mice]. Arzneimittelforschung. 1966 Apr;16(4):566-8. German.
PubMed PMID: 4863900.


20: Gerhards E, Kolb KH. [2-Benzolsulfonamido-5(beta-methoxy-ethoxy)-pyrimidine
(Glycodiazine). II. Metabolism of
2-benzolsulfonamido-5(beta-hydroxy-ethoxy)-pyrimidine, a blood sugar reducing
metabolite of glycodiazine in man]. Arzneimittelforschung. 1965
Dec;15(12):1375-9. German. PubMed PMID: 5899812.